BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Golfieri R, Marini E, Bazzocchi A, Fusco F, Trevisani F, Sama C, Mazzella G, Cavuto S, Piscaglia F, Bolondi L. Small (<or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT. Radiol Med. 2009;114:1239-1266. [PMID: 19697104 DOI: 10.1007/s11547-009-0439-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen L, Zhang L, Bao J, Zhang J, Li C, Xia Y, Huang X, Wang J. Comparison of MRI with liver-specific contrast agents and multidetector row CT for the detection of hepatocellular carcinoma: a meta-analysis of 15 direct comparative studies. Gut 2013;62:1520-1. [DOI: 10.1136/gutjnl-2013-305231] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
2 Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, Heimbach JK, Murad MH, Mohammed K. Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. Hepatology. 2018;67:401-421. [PMID: 28859233 DOI: 10.1002/hep.29487] [Cited by in Crossref: 139] [Cited by in F6Publishing: 133] [Article Influence: 27.8] [Reference Citation Analysis]
3 Nadarevic T, Colli A, Giljaca V, Fraquelli M, Casazza G, Manzotti C, Štimac D, Miletic D. Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2022;5:CD014798. [PMID: 35521901 DOI: 10.1002/14651858.CD014798.pub2] [Reference Citation Analysis]
4 Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, Štimac D. Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;10:CD013362. [PMID: 34611889 DOI: 10.1002/14651858.CD013362.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Sham JG, Kievit FM, Grierson JR, Chiarelli PA, Miyaoka RS, Zhang M, Yeung RS, Minoshima S, Park JO. Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma. J Nucl Med. 2014;55:2032-2037. [PMID: 25359880 DOI: 10.2967/jnumed.114.145102] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
6 Ramalho M, AlObaidy M, Burke LM, Dale BM, Gerber DA, Wong TZ, Semelka RC. MR-PET evaluation of 1-month post-ablation therapy for hepatocellular carcinoma: preliminary observations. Abdom Imaging 2015;40:1405-14. [PMID: 25906343 DOI: 10.1007/s00261-015-0436-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Chernyak V, Horowitz JM, Kamel IR, Arif-tiwari H, Bashir MR, Cash BD, Farrell J, Goldstein A, Grajo JR, Gupta S, Hindman NM, Kamaya A, Mcnamara MM, Porter KK, Solnes LB, Srivastava PK, Zaheer A, Carucci LR. ACR Appropriateness Criteria® Liver Lesion-Initial Characterization. Journal of the American College of Radiology 2020;17:S429-46. [DOI: 10.1016/j.jacr.2020.09.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Albiin N. MRI of Focal Liver Lesions. Curr Med Imaging Rev. 2012;8:107-116. [PMID: 23049491 DOI: 10.2174/157340512800672216] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
9 Wei Y, Liao R, Mahmood AA, Xu H, Zhou Q. pH-responsive pHLIP (pH low insertion peptide) nanoclusters of superparamagnetic iron oxide nanoparticles as a tumor-selective MRI contrast agent. Acta Biomater 2017;55:194-203. [PMID: 28363789 DOI: 10.1016/j.actbio.2017.03.046] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 6.6] [Reference Citation Analysis]
10 Tan CH, Low SC, Thng CH. APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review. Int J Hepatol. 2011;2011:519783. [PMID: 22007313 DOI: 10.4061/2011/519783] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
11 Qian LX, Liu YJ, Ding HG. Advances in imaging diagnosis of small hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2010; 18(5): 479-486 [DOI: 10.11569/wcjd.v18.i5.479] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
12 Sham JG, Kievit FM, Grierson JR, Miyaoka RS, Yeh MM, Zhang M, Yeung RS, Minoshima S, Park JO. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma. J Nucl Med 2014;55:799-804. [PMID: 24627434 DOI: 10.2967/jnumed.113.132118] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
13 Zhou Q, Wei Y. For Better or Worse, Iron Overload by Superparamagnetic Iron Oxide Nanoparticles as a MRI Contrast Agent for Chronic Liver Diseases. Chem Res Toxicol 2017;30:73-80. [DOI: 10.1021/acs.chemrestox.6b00298] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
14 De Cecco CN, Buffa V, Fedeli S, Vallone A, Ruopoli R, Luzietti M, Miele V, Rengo M, Maurizi Enrici M, Fina P, Laghi A, David V. Preliminary experience with abdominal dual-energy CT (DECT): true versus virtual nonenhanced images of the liver. Radiol Med 2010;115:1258-66. [PMID: 20852956 DOI: 10.1007/s11547-010-0583-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]